title: Optimization of multimeric human papillomavirus L2 vaccines.
abstract: We sought to define the protective epitopes within the amino terminus of human papillomavirus (HPV) type 16 minor capsid protein L2. Passive transfer of mice with rabbit antisera to HPV16 L2 peptides 17-36, 32-51 and 65-81 provided significant protection against vaginal HPV16 challenge, whereas antisera to 47-66, 108-120 or 373-392 did not. Vaccination with L1 virus-like particles induces a high titer, but generally type-restricted neutralizing antibody response. Conversely, vaccination with L2 11-88, especially multimers thereof, induces antibodies that neutralize a broad range of papillomavirus types, albeit at lower titers than for L1 VLP. With the intent of enhancing the immunogenicity and the breadth of protection by focusing the immune response to the key protective epitopes, we designed L2 fusion proteins consisting of residues ∼11-88 of eight divergent mucosal HPV types 6, 16, 18, 31, 39, 51, 56, 73 (11-88×8) or residues ∼13-47 of fifteen HPV types (13-47×15). The 11-88×8 was significantly more immunogenic than 13-47×15 in Balb/c mice regardless of the adjuvant used, suggesting the value of including the 65-81 protective epitope in the vaccine. Since the L2 47-66 peptide antiserum failed to elicit significant protection, we generated an 11-88×8 construct deleted for this region in each subunit (11-88×8Δ). Mice were vaccinated with 11-88×8 and 11-88×8Δ to determine if deletion of this non-protective epitope enhanced the neutralizing antibody response. However, 11-88×8Δ was significantly less immunogenic than 11-88×8, and even the addition of a known T helper epitope, PADRE, to the construct (11-88×8ΔPADRE) failed to recover the immunogenicity of 11-88×8 in C57BL/6 mice, suggesting that while L2 47-66 is not a critical protective or T helper epitope, it nevertheless contributes to the immunogenicity of the L2 11-88×8 multimer vaccine.
authors: Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States of America.
authors: Subhashini
authors: S
authors: Jagu
authors: Kihyuck
authors: K
authors: Kwak
authors: Balasubramanyam
authors: B
authors: Karanam
authors: Warner K
authors: WK
authors: Huh
authors: Vijayarangam
authors: V
authors: Damotharan
authors: Sudha V
authors: SV
authors: Chivukula
authors: Richard B S
authors: RB
authors: Roden
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D036022:Capsid Proteins / Q000737:chemistry / Q000276:immunology*; D000939:Epitopes / Q000737:chemistry / Q000276:immunology; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology*; D006801:Humans; D051379:Mice; D009500:Neutralization Tests; D009856:Oncogene Proteins, Viral / Q000737:chemistry / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000276:immunology*; D010455:Peptides / Q000737:chemistry / Q000276:immunology; D011817:Rabbits; D014621:Vagina / Q000276:immunology / Q000821:virology
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D000939:Epitopes; C063316:L2 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D010455:Peptides
references: Micron. 1999 Dec;30(6):597-623
references: 10544506
references: Nat Biotechnol. 1999 Jun;17(6):555-61
references: 10385319
references: Vaccine. 2003 Oct 1;21(27-30):4256-60
references: 14505907
references: Tuberculosis (Edinb). 2006 Mar;86(2):115-24
references: 16039905
references: Immunity. 1994 Dec;1(9):751-61
references: 7895164
references: Vaccine. 2009 Mar 18;27(13):1949-56
references: 19368776
references: Virology. 2000 May 10;270(2):254-7
references: 10792983
references: Virology. 1991 Apr;181(2):572-9
references: 1707567
references: Br J Cancer. 2006 Dec 4;95(11):1459-66
references: 17117182
references: Nat Med. 2007 Jul;13(7):857-61
references: 17603495
references: J Virol. 2007 Nov;81(21):11585-92
references: 17715230
references: Virology. 2012 Dec 5;434(1):110-7
references: 23051711
references: J Virol. 2009 Oct;83(19):10085-95
references: 19640991
references: Science. 1993 Nov 26;262(5138):1448-51
references: 8248784
references: Expert Rev Vaccines. 2007 Jun;6(3):381-90
references: 17542753
references: Nat Rev Cancer. 2006 Oct;6(10):753-63
references: 16990853
references: Int J Cancer. 2004 Aug 20;111(2):278-85
references: 15197783
references: Lancet. 2009 Jul 25;374(9686):301-14
references: 19586656
references: Bioinformatics. 2001 Dec;17(12):1236-7
references: 11751237
references: Virology. 1998 Jun 5;245(2):353-9
references: 9636375
references: J Virol. 2003 Aug;77(15):8386-93
references: 12857908
references: Virology. 2010 May 25;401(1):70-9
references: 20206957
references: Immunol Lett. 2004 Apr 15;92(3):259-68
references: 15081621
references: Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25
references: 16949997
references: J Virol. 2013 Jan;87(1):464-73
references: 23097431
references: J Virol. 2007 Dec;81(24):13927-31
references: 17928339
references: Vaccine. 2007 Mar 1;25(11):2001-10
references: 17239496
references: J Natl Cancer Inst. 2009 Jun 3;101(11):782-92
references: 19470949
references: Lancet. 2007 Jun 30;369(9580):2161-2170
references: 17602732
references: Vaccine. 2001 Jan 8;19(11-12):1496-502
references: 11163673
references: J Infect Dis. 2009 Apr 1;199(7):926-35
references: 19236279
references: J Virol. 1999 Jul;73(7):6188-90
references: 10364381
references: J Med Virol. 2008 May;80(5):841-6
references: 18360909
references: Nat Rev Cancer. 2002 May;2(5):342-50
references: 12044010
references: Virology. 2005 Jul 5;337(2):365-72
references: 15885736
references: J Virol. 2002 Oct;76(19):9798-805
references: 12208958
references: J Virol. 2010 Feb;84(3):1214-20
references: 19906917
references: Virology. 2007 Feb 20;358(2):266-72
references: 17010405
references: Lancet Oncol. 2005 May;6(5):271-8
references: 15863374
references: Virology. 2011 Jan 20;409(2):348-59
references: 21074234
references: J Virol. 2004 Jan;78(2):751-7
references: 14694107
references: Virology. 1995 Aug 1;211(1):204-8
references: 7544045
references: PLoS One. 2011;6(8):e23310
references: 21858066